知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.028 秒)

    SYSTEMS AND METHODS FOR DETERMINING RETINAL GANGLION CELL POPULATIONS AND ASSOCIATED TREATMENTS
    12.
    发明申请
    SYSTEMS AND METHODS FOR DETERMINING RETINAL GANGLION CELL POPULATIONS AND ASSOCIATED TREATMENTS 审中-公开

    公开(公告)号：US20180020908A1

    公开(公告)日：2018-01-25

    申请号：US15643402

    申请日：2017-07-06

    申请人： The Regents of the University of California

    发明人： Felipe A. Medeiros ,  Robert N. Weinreb ,  Linda M. Zangwill

    IPC分类号： A61B3/00 ,  G01N33/68 ,  A61B3/10

    CPC分类号： A61B3/0025 ,  A61B3/1005 ,  A61B3/102 ,  G01N33/6893 ,  G01N2800/168 ,  G01N2800/56

    摘要： A new combined index of structure and function (CSFI) for staging and detecting glaucomatous damage is provided. An observational study including 333 glaucomatous eyes (295 with perimetric glaucoma and 38 with preperimetric glaucoma) and 330 eyes of healthy subjects is described. All eyes were tested with standard automated perimetry (SAP) and spectral domain optical coherence tomography (SDOCT) within 6 months. Estimates of the number of retinal ganglion cells (RGC) were obtained from SAP and SDOCT and a weighted averaging scheme was used to obtain a final estimate of the number of RGCs for each eye. The CSFI was calculated as the percent loss of RGCs obtained by subtracting estimated from expected RGC numbers. The performance of the CSFI for discriminating glaucoma from normal eyes and the different stages of disease was evaluated by receiver operating characteristic (ROC) curves. The mean CSFI, representing the mean estimated percent loss of RGCs, was 41% and 17% in the perimetric and pre-perimetric groups, respectively (P

    Methods for treating glaucoma and macular degeneration
    13.
    发明授权
    Methods for treating glaucoma and macular degeneration 有权
    治疗青光眼和黄斑变性的方法

    公开(公告)号：US08669253B2

    公开(公告)日：2014-03-11

    申请号：US11716724

    申请日：2007-03-12

    申请人： Vasantha P. Rao ,  Patrick J. Casey ,  Peifeng Deng ,  Yuri K. Peterson

    发明人： Vasantha P. Rao ,  Patrick J. Casey ,  Peifeng Deng ,  Yuri K. Peterson

    IPC分类号： A61K31/41 ,  A61K31/53

    CPC分类号： G01N33/5044 ,  G01N33/5088 ,  G01N2333/4709 ,  G01N2333/91 ,  G01N2800/168

    摘要： Inhibition of geranylgeranylation of Rho GTPases and heterotrimeric G-proteins in the aqueous outflow pathway increases aqueous humor outflow, possibly through the tissue relaxation, and through altered cell adhesive interactions and actin cytoskeletal organization in cells of the outflow pathway. In addition, such inhibition is useful for treating age-related macular degeneration. The GGTase-I enzyme is a molecular target for lowering increased ocular pressure in glaucoma patients.

    摘要翻译： 抑制Rho GTP酶和异源三聚体G蛋白在水流出途径中的香叶基刺激，可能通过组织松弛以及通过流出途径细胞中细胞粘附相互作用和肌动蛋白细胞骨架组织的改变引起房水流出。 此外，这种抑制对于治疗年龄相关性黄斑变性是有用的。 GGTase-I酶是降低青光眼患者眼压升高的分子靶点。

    NORMAL-TENSION GLAUCOMA MODEL AND METHOD FOR EVALUATION OF TEST SUBSTANCES BY USING SAME
    14.
    发明申请
    NORMAL-TENSION GLAUCOMA MODEL AND METHOD FOR EVALUATION OF TEST SUBSTANCES BY USING SAME 失效
    用于评估试验物质的正常拉曼光学模型和方法

    公开(公告)号：US20100204311A1

    公开(公告)日：2010-08-12

    申请号：US12668838

    申请日：2008-07-11

    申请人： Takuma Hayashi ,  Yasuko Takahashi ,  Tomoko Yanagidaira ,  Shunichiro Taniguchi ,  Toshinori Murata

    发明人： Takuma Hayashi ,  Yasuko Takahashi ,  Tomoko Yanagidaira ,  Shunichiro Taniguchi ,  Toshinori Murata

    IPC分类号： A61K31/7088 ,  A01K67/00 ,  C12N5/00 ,  A01N1/00 ,  G01N33/00 ,  C12Q1/02 ,  C12Q1/68 ,  A61P27/06

    CPC分类号： G01N33/5088 ,  A01K67/0276 ,  A01K2227/105 ,  A01K2267/03 ,  A61K49/0008 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2800/168

    摘要： It is intended to provide a simple normal-tension glaucoma model capable of spontaneously, age-dependently and surly developing conditions similar to symptoms of normal-tension glaucoma which occurs more frequently in elder people, and a method of evaluating therapeutic effect on normal-tension glaucoma whereby a drug useful in treating and diagnosing can be conveniently screened by using the normal-tension glaucoma model. A normal-tension glaucoma model comprising a nonhuman mammal, which is deficient in a transcriptional regulator NF-κBp50 and thus spontaneously develops the normal-tension glaucoma symptom age-relatedly, an organ or a tissue thereof or cells collected from any of the same. A method of evaluating therapeutic effect on normal-tension glaucoma of a test substance which comprises administering or adding the test substance to the above-described nonhuman mammal, an organ or a tissue thereof or cells collected from any of the same, and measuring a morphological defect, cell count, pressure, the expression amount or activity strength of a protein, the expression amount of a nucleic acid and/or the activity strength of an antibody in the organ, tissue and/or cells as indication(s) for the evaluation.

    摘要翻译： 旨在提供一种能够自发地，年龄依赖性地和显着地发展类似于老年人更频繁发生的正常张力性青光眼症状的正常张力青光眼模型，以及评估对正常张力的治疗效果的方法 通过使用正常张力性青光眼模型，可以容易地筛选可用于治疗和诊断的药物的青光眼。 包含非转基因哺乳动物的正常张力性青光眼模型，其在转录调节因子NF-κBp50中是不足的，因此自发地发生与其相关的正常张力性青光眼症状年龄的器官或其组织或从任何 相同。 评价对被检物质的正常张力性青光眼的治疗效果的方法，其包括向所述非人类哺乳动物，器官或组织施用或添加测试物质或从其中任一种收集的细胞，并测量形态学 缺陷，细胞计数，压力，蛋白质的表达量或活性强度，核酸的表达量和/或器官，组织和/或细胞中抗体的活性强度作为评价指标 。